RECENT COMMENTS

Kathy Redmond: Readers may have noticed that ESO has deleted a number of comments on this article. This is because [...]   »Read more

Pongsri (Sex and cancer): I teach body image and sexuality in cancer survivors for specialty 4 month cancer nurse program. Thi [...]   »Read more

DR Jennifer L Scott (Sex and cancer): Togehter with my colleague Prof Karen Kayser I have published a review of RCT of interventions to en [...]   »Read more

Dr O. Abimbola Oluwatosin (Sex and cancer): I teach sexuality in Nursing at post graduate level. This article is very useful and will be added t [...]   »Read more

Dr. Yannis Vassiliou (political oncology): A great article, well done! I was deeply disappointed by the comments of the Turkish colleagues, wh [...]   »Read more

 

Article type: Spotlight on...

Keywords: Anna Wagstaff, World Conference for Science Journalists, cancer breakthroughs, informing attitudes and beliefs about cancer, .

This article has 0 comments

Facebook Twitter Share - Send - Print - Pdf

 

Should we expect better from the media?

A conversation with health journalists

» Anna Wagstaff

From California’s wired-up silicon valley to the remote rural hinterlands of central Africa, from the Graeco-Roman cultures of southern Europe to Scandinavia with its Viking heritage, everyone harbours attitudes to cancer that are deeply rooted in their culture, are shaped in part by the experiences of previous generations – parents, grandparents, great uncles – and in turn shape the life choices they make.

A great weight of unnecessary suffering and death could be avoided, if only it were possible to influence those attitudes – and consequently behaviours – by helping all these people understand the growing evidence-based consensus on how they can minimise their chances of getting cancer, catch it early should it develop, and find the treatment options that give them the best chance of surviving with their quality of life intact, or at least to continue living a full life and finally achieve a dignified and pain-free death.

Journalists are well-placed to influence public attitudes through what they broadcast and publish in print and online, yet the mass media constantly distorts key messages by sensationalist reporting about deadly hidden hazards, wonder foods and breakthrough cancer cures. Is it journalists – irresponsible, unprofessional and out to make a quick impact – who are to blame? Are health professionals misguided in expecting the mass media to take on the role of a public health agency, even if it could? Is it possible to improve the quality of coverage of cancer in the mass media?

These were some of the questions ESO put to an international gathering of journalists convened in London last July at the 2009 World Conference of Science Journalists. More than one hundred journalists from all over the world took part in two sessions, one on reporting cancer breakthroughs, the other on informing attitudes and beliefs about cancer. The sessions opened up a welcome dialogue about how health and science journalists see their role, and what can be done by everyone with an interest in promoting cancer control to improve the service the media provides its readers, viewers and listeners on cancer-related stories.

 
COMMENTS (0)
When submitted, your comment will be moderated. Messages which may be considered defamatory, which incite hatred or contain foul or abusive language, or are gratuitously offensive, will not be published. Please ensure that your comments are concise and relevant to the topic in question. Off-topic comments and comments without a username will not be published.

ESO reserves the absolute right not to publish comments.
  Name (required)
  E-mail (will not be published) (required)
  Captcha code (required)

CancerWorld invites you to visit:

 
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eisai, Eli Lilly, Genomic Health, GlaxoSmithKline, Merck and Novartis.